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Hedgehog Signaling Inhibitors and Their Importance for Cancer Treatment 
Haileselassie Tefera, Ms. Human Biology. Haileselassie.tefera@jacks.sdstate.edu 
Biology and Microbiology Department, South Dakota State University, Brookings, SD 
ABSTRACT: The Hedgehog (Hh) signaling pathway plays a crucial role during embryonic 
development as well as tissue maintenances in adults. Deregulated Hh signaling has been 
implicated in different diseases and conditions including cancer. Previously, the mechanisms of 
Hh signaling pathway and its role in cancer formation have been studied and has led to the 
development of therapeutic drugs. Among those agents, vismodegib and sonidegib are FDA 
approved drugs to treat basal cell carcinoma and other cancers. Up to date, several hedgehogs 
(Hh) signaling inhibitors and drugs have been made and evaluating for cancer treatment. In this 
review, I will discuss the mechanisms of action of Hh signaling pathway, targeted components, 
and Hh inhibitors and clinical importance as well as side effects, current evidences, and drug 
resistance.  
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INTRODUCTION 
The hedgehog gene was discovered first in 1980’s by Christiane Niisslein Volhard and Eric 
Wieschaus when they studied segmentation in Drosophila melanogaster(1). Mutation of this gene 
affected the number of segments observed and polarity in fruit fly. After Christiane Niisslein 
Volhard and Eric Wieschaus discovery, hedgehog signaling has significantly been studied by 
different scientists and numerous efforts have been made to investigate the diseases associated 
with hedgehog signaling pathway. The hedgehog pathway plays a crucial role in embryonic 
development, cell growth and differentiation and segmentation in vertebrates as well as in 
annelid (2, 3). This signaling pathway is responsible for the correct formation of limbs, digits, 
brain, bone, oogenesis, spermatogenesis and many other cells and structures during early 
embryogenesis (3). In adult vertebrates, the hedgehog signaling pathway is mostly inactive and 
involves in tissues and organs(4). Mutations that occur during embryonic development that affect 
hedgehog signaling pathway are linked to developmental disorders and mutations that occur 
during somatic development in adults associated with multiple forms of cancers (5).  
Researchers spent substantial amount of time targeting the hedgehog signaling pathway 
inhibitors to develop potential anticancer agents. Smoothened (SMO) is the primary regulatory 
protein that many researchers targeted including Ptch1, GLI and developed a lot of Hh signaling 
pathway inhibitors. Even if multiple Hh agents have been made, only two drugs get approved by 
FDA and the rest needs some type of modification and additional studies in order to use as a 
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cancer treatment. These drugs demonstrated and used as monotherapies and others in 
combination with other treatments. Most of them showed a promising result upon investigating 
on model organisms.  
Hedgehog Ligands  
The three orthologues that involve in hedgehog signaling pathway in vertebrates are Sonic Hh 
(Shh) the best studied pathway, Indian Hh (Ihh) and Dessert Hh (Dhh). Each Hh ligands displays 
different expression and function in the cell. For example, sonic hedgehog is very important for 
formation of limbs, neural tube, somites, and affects epithelial tissues developments. Indian Hh 
signaling is essential for bone growth, chondrocyte development and formation of the primitive 
endoderm. Dessert Hh expression mostly limited to gonads and Schwann cells formations (3, 5). 
These ligands mediate the Hh signaling pathway at the primary cilium where clusters of 
receptors found, and upon activation, signaling cascades takes place during embryogenesis and 
tissue homeostasis (3, 6). In the absence or overexpression of these ligands and defect at the 
primary cilia, the Hh signaling pathway causes developmental disorders and abnormalities in 
tissues and organs. Hh pathway requires primary cilia in order to regulate and cascade molecular 
signaling and induce gene transcription(7). 
Hedgehog signaling pathway and Key Components  
There are many positive and negative regulatory components of hedgehog pathway to transduce 
activation and inhibition of signaling pathway. Patched, GLI, smoothened (SMO) and SUFU are 
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some of the key components. Protein kinases like protein Kinase A, glycoprotein synthase 
Kinase 3 beta, and casein Kinase 1 also play a major role in the signaling and phosphorylation 
process of Hh signaling (3, 8). Understanding the basic concepts of Hh signaling pathway 
activation and it’s components help to select and develop the appropriate drugs for specific 
cancer.  
Patched is a 12-span transmembrane Hh receptor protein which has a negative regulatory 
function at the primary cilia. It is involved as a negative feedback mechanism to regulate Hh 
signaling activity in embryonic cell as well as tissue repairs. In the absence of Hh ligand, this 
transmembrane protein placed at the cilia prevents the accumulation of smoothened and therefore 
inhibit the Hh signaling pathway (3).  
Smoothened (SMO) is a 7-transmembrane G protein-coupled like protein receptor which, leads 
to the activation of Hh pathway by activating GLI transcription factors. Smoothened is repressed 
by Ptch1 to inhibit Hh pathway (8, 9). Glioma-associated oncogene (GLI) is a transcription 
factor that mediates the response of transcription of the target gene. In mammals, GLI 1 and 2 
are Hh signaling pathway activators. When these transcriptional activators are phosphorylated by 
protein kinases like PKA, GSK3β and CK1, lead to generate a GLIR which is a transcriptional 
repressor and results in inhibitions of Hh pathway target gene transcription in the nucleus (3, 9-
11).  
SUFU is another intracellular component that negatively controls the activation of Hh signaling 
pathway. It directly binds to the GLI protein in the cytoplasm and blocks its activation and 
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nuclear localization and forms a repressor protein complex that can suppress the Hh gene 
expression (12).   
Signaling pathway in the absence of Hh ligands 
Hh signaling pathway is not always active in adult vertebrates. In the absence of Hh ligands, 
Ptch1 activated and repress smoothened by sitting and preventing its accumulation on the 
primary cilia. Primary cilium is where the activation and inhibition of Hh signaling started at the 
membrane before series of signaling cascades takes place in the cytoplasm and nucleus. When 
SMO inhibited by Ptch1, it cannot dislocate to the cytoplasm and dissociate SUFU-Gli complex. 
The SUFU and GLI complex in the cytoplasm then get phosphorylated by PKA, GSK3β and 
CK1which lead to proteolytic process to produce repressor protein (3, 13). SUFU is a negative 
regulator and suppress GLI and inhibiting its translocation to the nucleus. The SUFU and GLI 
complex generates a new repressor protein called GLIR which transport to the nucleus and inhibit 
hedgehog signaling target gene expression (3). (Fig 1A below). Along with other Hh key 
components, signaling pathway inhibited. 
Signaling pathway in the presence of Hh ligands 
In the presence of Hh ligand, it’s signaling pathway get activated and affect the cells activity. Hh 
ligand first converted to its active form and binds to the Ptch1 which is a 12-transmembrane 
protein and Hh ligand receptor (12). The inhibitory effect of Ptch1 removed from the SMO and 
then this 7TM translocate to the primary cilia and dissociate Suppressor of Fused (SUFU) and 
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GLI complex. SUFU-GLI complex was supposed to generate a repressor protein and inhibit the 
Hh signaling that target gene expression in the nucleus but when this complex dissociated, GLI, 
a transcription factor activate and translocate to the nucleus to induce a gene transcription for Hh 
target genes(3). (see Fig 1 B below). Including many other key components this is the activation 
pathway of Hedgehog signaling. 
    
Fig. 1. General hedgehog signaling pathway: Activation and inhibition of hedgehog signaling pathway 
by different key components. (A) patch1 inhibit SMO at the primary cilia in the absence of Hh ligands and 
SUFU-GLI complex formed. When GLI phosphorylated by PKA, GSK3β and CK1 which generate a GLIR 
which in turn inhibit Hh gene expression. (B) In the presence of Hh signaling ligands, Shh, Ihh or Dhh 
binds and inhibit Ptch1. SMO activated and dissociate SUFU and GLI complex and no GLIR produced to 
suppress transcription but GLI move to the nucleus to induce activation of target gene. 
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Molecular mechanisms of Hh ligands and key components 
The molecular mechanisms how Hh ligands interact with Ptch1 and inhibitory effect on 
smoothened is unclear. Recent study showed that the cytoplasmic tail contributed to inhibitory 
function of Ptch1 on smoothened and Hh ligands interaction (13). In this study, when the C-
terminus amino acid truncated on the transmembrane segment, Ptch1 activity disrupted and 
smoothened suppression relieved and leads to constitutive activation of Hh signaling pathway. 
Ptch1 with truncated extracellular loop and normal cytoplasmic tail fully suppressed smoothened 
activity but Hh ligands did not bind. This research also discussed truncated tail and loop of 
smoothened impaired its accumulation at the cilia and downstream activation of Hh signaling 
pathway. 
Cancer and Treatments Using Hh Inhibitors 
The detailed study of activation and inhibition of the Hh pathway helped researchers to develop 
drugs and to turn their attention towards the cancer. Currently, the main target of cancer research 
regarding drug therapies including cancer prevention is smoothened. The Hh signaling is able to 
maintain cancer stem cells by feeding the surrounding microenvironments of the tumor to grow 
so, researchers targeted by inhibiting the over expression of Hh signaling pathway in different 
cancer and related diseases to treat the patients (3). Tumor invasion and progression inhibited by 
Hh signaling inhibitors in clinical patients and model organism. In some studies the hedgehog 
(Hh) pathway expression was limited in normal adults but in cancer cells Hh was overexpressed 
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and facilitates the growth of the tumor (14). Basal Cell Carcinoma (BCC) is the most common 
skin cancer in human and overexpression of Hh pathway is a key driven pathogenesis. 
Vismodegib and sonidegib are the only two FDA approved drugs. Nowadays BCC incidence is 
increasing in the world and different drug developers and researchers are doing tremendous 
effort to develop therapeutic drugs and showing promising results (15). Advanced BCC patients 
usually use vismodegib and sonidegib in combination or separately. As figure 2 indicated, the 
overexpression of Hh pathway in BCC tumor show regression and decrease in size after 
treatment. These drugs able to promote adaptive immune cells to the tumor microenvironment 
(4).  
Fig.2. Immune cells infiltration after Hh pathway inhibitors treatments. A biopsy taken from 
patients before and after treatment. (A)Immunostaining of patients’ biopsy revealed increaseCD8 cells 
in tumor environments.  (B) upregulation of MHC class I cells expression in intratumor and peritumoral 
area. 
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Drugs that targeted Hh signaling pathway 
In recent years a major effort has been made and developed many inhibitors that blocked Hh 
signaling pathway at different steps. The Hh signaling pathway key components that targeted for 
these therapeutic agents are Smoothened, GLI, Hh orthologue and Hhat. As discussed above, 
most of the Hh signaling pathway inhibitors are targeted smoothened. Some cancers treated with 
single Hh pathway inhibitors and others treated with a combination of Hh antagonist drugs.  
Therapeutic drugs target Smoothened 
Most of those inhibitors are specifically acted on smoothened to block the expression of Hh 
signaling in tumor and its microenvironments (16). Among these therapeutic drugs Vismodegib 
and Sonidegib have been approved by Food and Drug Administration (FDA). Saridegib, 
Taladegib and Cyclopamine and its derivatives also target SMO receptor.  
Vismodegib is a small molecule and the first hedgehog signaling pathway inhibitor which act on 
Smoothened protein to prevent its accumulation in primary cilia (17). This inhibitor approved by 
FDA for metastatic basal cell carcinoma. In one study involving 704 basal cell carcinoma 
patients showed a partial response rates of 62 % and currently Vismodegib is in clinical trials for 
other cancers as monotherapy and in combination with other drugs (3, 17). In some clinical trials 
of Medulloblastoma patients, Vismodegib showed an ineffective result because of mutation of 
SMO protein and in fact its low solubility (12).  
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Sonidegib is the second FDA approved smoothened inhibitor for basal cell carcinoma patients 
followed by surgery, radiation treatment and or patients who is not candidate for surgery and 
radiation (12). Otsuka et al studied 23 patients with basal cell carcinoma after Vismodegib and 
Sonidegib treatments(4). They found these drugs altered the tumor cell populations and promote 
adaptive immunity in tumor microenviroments. After these therapuatic drugs treatment, the 
patients showed influx of some immune cells in the tumor microenviroments (10). Both 
Vismodegib and Sonidegib are in clinical trials to treat lung and other solid tumors(3). Figure 3 
below showed the modification of the orginal sonidegib compound in order to improve toxicity 
and solubility (18) and also chemical structure of vismdegib (19). 
      
  
I 
II 
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Cyclopamine is naturaly occuring compound and effective smoothened inhibitor which is found 
in the corn lily. This compound found in 1950’s in research done due to a lambs born with one 
Fig. 3. Modification of sonidegib. 1. Three core regions namely A, B, and C of compound I get 
modified. 2. Region A modified with Nitrogen in the pyridine moiety and dimethyl group added to 
improve toxicity, Region B modified, and methyl added to increase potency and finally region C 
modified with F3CO in order to favor absorption as shown on compound II. R400, R473, and E518 are 
drug binding pockets for SMO. Arginine (R) and Glutamic acid (E) are the amino acids associated with 
this binding site. Compound III is the first FDA approved drug, vismodegib. 
III 
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eye and it tooks scientists about ten years to figured it out (17). Cylopamine has been intensively 
studied and demonestrated to inhibit melanoma, colon, pancreatic, prostate, lung and other 
cancers but its therapauetic usage as Hh inhibitor for human is limited due to poor property and 
its side effects of low solubility in the body under normal condition (3). In order to overcome this 
limitation some other cyclopamine derivaties developed which include KAAD cyclopamine and 
Saridegib with a potentially improved soubility in model animals but iys clinical trials terminated 
due to inefficents clinical benefit and for patients saftey (3, 9).  
Therapeutic drugs target Gli 
The other target for hedghog signaling pathway inhibitors is Gli transcription factor (3, 9, 20). 
This target protein is important to overcome drug resistance property of smoothend. Among the 
Gli inhibitors, GANT58 and GANT61 are small molecules and suppressed the proliferation of 
rhabdomyosarcoma, prostate, colon, and ovarian cancers and further study showed potential 
distruption of Gli phosporaylation and Hh inhibition (3, 21).  Arsenic trioxide (ATO) is also Shh 
inhibitor by blocking Gli protein and used to treat patients with white blood cells cancer and 
currently it is in clinical trials for solid tumors including pancreatic cancer (3, 22). 
Therapeutic drugs target Hh Ligands 
Hedgehog signaling pathway ligands (Shh, Dhh and Ihh) are also target for therapeutic agents to 
block abnormal proliferation of cancerous cells in tumor microenvironments (3, 8, 16). All the 
three ligands were able to block by a monoclonal antibody 5E1. 5E1 has been proved to suppress 
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pancreatic and medulloblastoma in mouse model. An acyltransferase (Hhat) which is essential 
hedgehog (Hh) signaling pathway enzyme targeted by a small molecule RUSKI-43 and RUSKI-
201 (3, 23). 
Hh inhibitors Target Treatment/Repression Side effects 
Vismodegib SMO FDA approved for metastatic BCCs FDA approved, ongoing 
clinical trials for other 
cancers and Resistance 
Cyclopamine  SMO Inhibit Tumor like glioma, melanoma, 
prostate, colon and lung cancers 
Due to low solubility, it is 
not approved by FDA 
Saridegib SMO Ovarian, medulloblastoma and 
pancreatic cancer 
Potent and detrimental 
effects 
Taladegib SMO Medulloblastoma in model animal Effective only in BCCs 
(mice) 
Sonidegib SMO BCCs (CR)4, lung, and advanced solid 
tumors. 
FDA approved, ongoing 
clinical trials for other 
cancers and resistance 
Itraconazole SMO FDA approved for antifungal disease Ongoing clinical trials. 
Table 1. Summary of hedgehog signaling pathway inhibitors and its implication in cancer. 
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GANT58 & 61 GLI Prostate, colon and ovarian Ongoing clinical trials 
5E1 Hh ligands Medulloblastoma and pancreatic No clinical trial yet 
RUSKI-43 Shh, Hhat 
& PDE4 
Breast and pancreatic tumors No clinical trial yet 
Glasdegib SMO BCC Under clinical investigation 
 
Drug resistance challenges, and recent studies on small molecules 
As I discussed above, SMO showed a resistance for vismodegib and sonidegib therapeutic drugs. 
It has been a major challenge for FDA approved Hh pathway drug users to overcome the drug-
resistant property of SMO mutant (12). A recent research was done on Hh inhibitors and Hh 
dependent tumors, and they found a promising result for mutant SMO and sonidegib and 
vismodegib resistance tumors (24). In this study, a compound called 2’, 4’, 5’, 3, 4-
pentamethoxychalcone was found to be the most powerful Hh pathway inhibitor by binding at 
the same binding site as Cyclopamine. This drug acts on SMO receptor. They farther 
investigated on the Hh driven tumors in which constitutive activation of Hh target gene present 
and loss of Ptch1 function. Small concentration of this compound was able to decrease the 
mRNA levels of the downstream Hh target genes.  
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Many cancer patients who took vismodegib and sonidegib treatment showed drug resistance at 
the SMO receptor due to its rapid mutation, but this new drug is able to act on drug-resistant 
SMO mutant and it will have a potential impact for future cancer treatments. In recent study by 
F. Wang et al., derivative of vismodegib found to have a long-acting Hh inhibitor activity 
compared to vismodegib itself (25). In this study they synthesized a deuterium-hydrogen 
analogue of vismodegib and found to be more stable when administered in mice. As summarized 
in table 2 and Figure 4 below, a lot of small molecules and active plant products showed a 
significant inhibitory effect on Hh signaling pathway and further study and modification of these 
compounds while have great therapeutic treatment for Hh-driven cancers (12, 23, 26-28). 
Basal Cell Carcinoma (BCC) is the most common skin cancer in human and overexpression of 
Hh pathway is a key driven pathogenesis. Vismodegib and sonidegib are the only two FDA 
approved drugs. Nowadays BCC incidence is increasing in the world and different drug 
developers and researchers are doing tremendous effort to develop therapeutic drugs and 
showing promising results (15). Advanced BCC patients usually use vismodegib and sonidegib 
in combination or separately. As figure 3 indicated, the overexpression of Hh pathway in BCC 
tumor show regression and decrease in size after treatment. These drugs able to promote adaptive 
immune cells to the tumor microenvironment (4). 
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Compound Category/Source Action and Target Limitation and side effect 
Eggmanone  Thiophenes  PDE4/SMO Low solubility, potent 
RUSKI 39, 41,43 and 50 Thiophenes Hhat/Hhh Potent and cytotoxicity 
Bisamide compounds pyridines Kinases Low solubility and strong bind 
with plasm 
Tetrahydrothiazolo[5,4-
c] pyridine 
Pyridine  SMO High potency and large size 
Hh003 pyridine SMO Induce apoptosis, and strong 
inhibiting activity in mouse 
model compared to Vismodegib 
Table 2. Summary of recent design of Hh signaling pathway inhibitors. The following small molecules 
and natural compounds are new and modified forms of known Hh inhibitors and needs further studies 
before clinical trial. These small molecules and active plant products might use as a source for 
development of newly synthetic Hh signaling pathway inhibitor. 
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HEK293 and NIH3T3-
GRE 
Pyridine Hh/Wnt but 
specific target not 
identified 
Inhibit Wnt and Hh pathway 
simultaneously   
VD3 Vitamin D3 
analogs 
SMO Promote hypercalcemia 
SANT-2 Benzimidazoles SMO High potency  
Robotnikinin  Macrolactone 
analog 
SMO/Shh Cytotoxic and poor solubility 
LAB687 Biphenyl 
derivative 
SMO Weak affinity 
Colubrinic and betulinic 
acid 
Pentacyclic 
triterpenes 
GLI/BCL-2 Good candidates for clinical 
trial 
Genistein Natural /plant GLI1 Needs modification 
Curcumin Natural /plant Shh, GLI Needs modification 
Resveratrol Natural /plant GLI Needs modification 
Hedgehog Signaling Inhibitors and Their Importance for Cancer Treatment     19 
 
Epigallocatechin-3-
gallate 
Natural /plant Ihh/GLI Needs modification 
Arsenic trioxide Inorganic 
compund 
GLI FDA approved for Leukemia 
Glabrescione B and 
Isoflavone 
Extracted from 
seeds 
GLI Further study  
LEQ-506 and TAK-441 Small molecules SMO Under clinical trials 
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Fig. 4. Series of different groups of compounds that inhibit Hh signaling pathway. These 
chemicals showed a promising result by inhibiting the Hh pathway at different target regions of the 
cells. Modification of these compounds might result effective therapeutic drugs for Hh-dependent 
cancers.  
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 Conclusion  
The discovery of the Hh pathway played an important role in the understanding of normal 
vertebrate development (29). Abnormal activation of Hh is involved in cancer. Most studies 
focused on SMO and other key components to inhibit the Hh pathway. In recent years numerous 
hedgehogs signaling pathway inhibitors specifically target Smoothened have been came out and 
undergo preclinical and clinical trials. These Hh pathway inhibitors showed a significant 
blockage on the tumor growth and microenvironments in model organism (30). Vismodegib and 
sonidegib are the only FDA approved drugs for different cancerous diseases. Unfortunately 
Smoothened showed a drug resistance by changing its form after given multiple dosages. 
Scientists acquired a different mechanism to overcome this side effect and develop other drugs 
that target other than Smoothened like Gli, Hh orthologues, and Hh enzyme acyltransferase 
(Hhat). In order to overcome drug resistance, further research on the key components of 
signaling cascade might be crucial. In addition, studying other Hh signaling pathway 
components, developing new drugs and further clinical trials on the other drugs will lead to 
develop new effective drugs and better cancer treatment.  
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